Sorafenib (Nexavar, BAY 43-9006)

DRUG2 trials

Sponsors

Bayer

Conditions

Carcinoma, Renal Cell

Unknown Phase

Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma

CompletedNCT01508364

BayerCarcinoma, Renal Cell

Start: 2012-07-31End: 2013-12-31Updated: 2015-01-21

Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma

CompletedNCT01982097

BayerCarcinoma, Renal Cell

Start: 2014-01-10End: 2017-12-07Updated: 2018-02-07